Francis Michael Patafio1, D Robert Siemens2, Xuejiao Wei1, Christopher M Booth3. 1. Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Queen's University, Kingston, ON; 2. Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Queen's University, Kingston, ON; ; Department of Oncology, Queen's University, Kingston, ON; ; Department of Urology, Queen's University, Kingston, ON; 3. Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Queen's University, Kingston, ON; ; Department of Oncology, Queen's University, Kingston, ON; ; Department of Public Health Sciences, Queen's University, Kingston, ON.
Abstract
INTRODUCTION: The incidence of bladder cancer varies by gender. Whether differences exist between women and men in extent of disease, treatment, and outcome is not well-described. We evaluate gender differences in bladder cancer using a population-based cohort. METHODS: Electronic records of treatment were linked to the population-based Ontario Cancer Registry to identify all patients with bladder cancer treated with cystectomy or radical radiotherapy (RT) in Ontario between 1994 and 2008. We compare extent of disease at time of cystectomy, treatment, and outcomes between women and men. RESULTS: In total, 5259 patients with bladder cancer were treated with cystectomy or radical RT; of these, 25% (n = 1296) were women. There was no gender difference in the proportion of patients treated with cystectomy (75% of women [974/1296], 73% of men [2905/3963], p = 0.189). At the time of cystectomy, women were more likely to have muscle-invasive disease (86% [836/974] vs. 80% [2335/2905], p < 0.001), but less likely to have lymph nodes dissected (68% [664/974] vs. 76% [2210/2905], p < 0.001]. Among the 2944 patients with muscle-invasive urothelial carcinoma treated with cystectomy, use of neoadjuvant (5% vs. 4%, p = 0.419) and adjuvant chemotherapy (18% vs. 20%, p = 0.190) did not differ significantly between genders. Five-year cancer-specific survival and overall survival of the full cohort did not differ between women and men (38% vs. 39%, p = 0.522; 33% vs. 33%, p = 0.795). CONCLUSIONS: This population-based cohort did not demonstrate any substantial differences in extent of disease, treatment, or outcome between women and men treated with cystectomy or radical RT for bladder cancer.
INTRODUCTION: The incidence of bladder cancer varies by gender. Whether differences exist between women and men in extent of disease, treatment, and outcome is not well-described. We evaluate gender differences in bladder cancer using a population-based cohort. METHODS: Electronic records of treatment were linked to the population-based Ontario Cancer Registry to identify all patients with bladder cancer treated with cystectomy or radical radiotherapy (RT) in Ontario between 1994 and 2008. We compare extent of disease at time of cystectomy, treatment, and outcomes between women and men. RESULTS: In total, 5259 patients with bladder cancer were treated with cystectomy or radical RT; of these, 25% (n = 1296) were women. There was no gender difference in the proportion of patients treated with cystectomy (75% of women [974/1296], 73% of men [2905/3963], p = 0.189). At the time of cystectomy, women were more likely to have muscle-invasive disease (86% [836/974] vs. 80% [2335/2905], p < 0.001), but less likely to have lymph nodes dissected (68% [664/974] vs. 76% [2210/2905], p < 0.001]. Among the 2944 patients with muscle-invasive urothelial carcinoma treated with cystectomy, use of neoadjuvant (5% vs. 4%, p = 0.419) and adjuvant chemotherapy (18% vs. 20%, p = 0.190) did not differ significantly between genders. Five-year cancer-specific survival and overall survival of the full cohort did not differ between women and men (38% vs. 39%, p = 0.522; 33% vs. 33%, p = 0.795). CONCLUSIONS: This population-based cohort did not demonstrate any substantial differences in extent of disease, treatment, or outcome between women and men treated with cystectomy or radical RT for bladder cancer.
Authors: Matthias May; Christian Stief; Sabine Brookman-May; Wolfgang Otto; Christian Gilfrich; Jan Roigas; Mario Zacharias; Wolf F Wieland; Hans-Martin Fritsche; Ferdinand Hofstädter; Maximilian Burger Journal: World J Urol Date: 2011-10-09 Impact factor: 4.226
Authors: Neal D Freedman; Debra T Silverman; Albert R Hollenbeck; Arthur Schatzkin; Christian C Abnet Journal: JAMA Date: 2011-08-17 Impact factor: 56.272
Authors: R Christopher Doiron; Melanie Jaeger; Christopher M Booth; Xuejiao Wei; D Robert Siemens Journal: Can Urol Assoc J Date: 2016 Sep-Oct Impact factor: 1.862
Authors: Sridhar T Narla; Daniel S Bushnell; Caitlin M Schaefer; Mehdi Nouraie; Justin T Tometich; Timothy W Hand; Carlton M Bates Journal: Am J Pathol Date: 2020-12-30 Impact factor: 5.770